Racura Oncology (ASX: RAC) - A High-Risk, High-Reward Oncology Play
Racura Oncology (ASX: RAC) is executing on a bold clinical strategy centered on RC220 (bisantrene reformulation), targeting both cardioprotection and enhanced anticancer activity in combination with doxorubicin. The company has dosed its first patient in a Phase 1 solid tumor trial, expanded into South Korea, and strengthened its clinical leadership team, all while maintaining disciplined cash management (A$13.67m at June 2025) to fund operations into 2026. Though early-stage, RAC presents a compelling mid- to long-term optionality scenario for investors with conviction in cardio-oncology and specialty chemotherapy.
European Lithium (ASX: EUR) — the Push toward European Lithium Independence
European Lithium is positioning itself as a future supplier of battery-grade lithium to Europe, with the Wolfsberg Project in Austria advancing through permitting, engineering, and early-stage financing activities.
BrainChip Holdings (ASX: BRN): High-Optionality Growth Play
BrainChip is a pioneer in ultra-low-power, neuromorphic AI processing, anchored by its Akida spiking neural network architecture. With US$13.5 million cash as of June 2025, the company is funding aggressive commercialisation efforts, including next-gen Akida 2.0, Pico devices, and defence / edge-AI partnerships. While financial performance is still pre-profit, recent commercial wins, deep IP protection, and product roadmap momentum provide compelling optional upside. Key risks include cash burn, technology adoption, and scaling edge-AI deployments.
Zip Co Limited (ASX: ZIP) — From BNPL Pioneer to Global Fintech Contender
Zip closed FY25 with what we consider a genuine inflection point: a record A$13.1bn in TTV and A$170.3m of group cash EBTDA — a level of profitability that would’ve sounded fanciful 18 months ago. The US arm is now the locomotive of the group, while ANZ has quietly rebuilt its margin spine. Momentum spilled straight into 1Q FY26, with TTV of A$3.9bn and cash EBTDA of A$62.8m, prompting management to hike US TTV guidance and expand the buyback to A$100m.
Investigator Silver (ASX: IVR)- Positions for Catalysts Amid Strengthening Silver Market
Investigator Silver (ASX: IVR), formerly known as Investigator Resources, is moving through one of the most strategically important phases in its history. The company is advancing the Paris Silver Project, Australia’s highest-grade undeveloped primary silver deposit, while simultaneously delivering exploration wins across its 100%-owned Peterlumbo tenement and progressing copper-gold targets at Uno Morgans.
Control Bionics (ASX: CBL) - This microcap's share price could explode higher from here!
The small-cap medical-tech company, Control Bionics, has just taken steps that could catapult it far beyond its current size. Its core product, a wearable sensor that translates even the faintest muscle or nerve signals into computer commands, is already approved and helps people with severe physical disabilities communicate and interact. Recently, the company announced that it had integrated a significant tech giant’s brain-computer interface protocol into its devices.